Verdú M,¹ Colomer A,¹ Erill N,¹ Roman R,² Górriz M, ^1,2 Ibáñez R,¹ Cordon-Cardo C,¹ Puig X.^1,2

¹HISTOPAT Laboratoris, Barcelona, Catalonia, Spain & ²BIOPAT. Biopatologia Molecular, Grup Assistència.

Background: Non-small cell lung cancer (NSCLC) is classified in two main categories: adenocarcinoma (AC), which includes bronchioloalveolar carcinoma (BAC), and squamous cell carcinoma (SCC). Activating mutations and increased copy number of the EGFR gene have been reported in tumors from patients with NSCLC with increased response rate to tyrosine kinase inhibitors (TKIs). There is […]

Colomer A, Erill N, Verdú M, Román R, Górriz M, Ibáñez R, Menoyo A, Cordon-Cardo C, Puig X.

^{BIOPAT, Grup Assistència, HISTOPAT Laboratoris, Barcelona, Spain; and Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York, United States.}

Background: Activating mutations of the EGFR gene were identified in tumors from patients with non small cell lung cancer (NSCLC) that responded to therapy with tyrosine kinase inhibitors (TKIs). More recently, survival has been reported to significantly increase amongst patients carrying a […]

M. J. Donovan, A. Kotsianti, A. Colomer, M. Verdú, M. Clayton, H. Pang, S. Hamann, C. Cordón-Cardó, X. Puig.

Background: The association of EGFR mutations with bronchoalveolar carcinoma (BAC) / non-small cell lung cancer (NSCLC) and the therapeutic and prognostic variability reported for lung cancer has reinforced the need for more accurate NSCLC sub-classification. The present study utilizes clinical data, immunohistochemistry (IHC), molecular analyses, and quantified immunofluorescent multiplexing (QIFM) to develop a systems pathology model for NSCLC. Methods: 73 NSCLC cases; […]